City IP leaders Bird & Bird and Taylor Wessing have raised eyebrows among rival patent specialists after accepting instructions to act for opposing sides of the industry in the highly competitive pharmaceuticals market.

Both firms, which traditionally act for research-based companies, have recently taken the unusual step of acting for generic-based companies against pharmaceuticals giant GlaxoSmithKline, a move rivals claim is courting potential business conflicts.